SQLite Web: event_store.db

Update row sig_a38cd6451b2d in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt","article_chars":3915,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_69c734a4d315fedb","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt","content_type":"text/plain","enriched_at":"2026-04-17T05:09:54.047783+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt","source_event_id":"evt_8b0b2c484877","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"d16f6360ada0dfb1","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-16","2025-08-11","2020-03-15","2027-03-15"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"equity","name":"Paul Mahon","relevance":"high","symbol":"","type":"insider_reporting_person"},{"asset_class":"equity","name":"United Therapeutics Corporation Common Stock","relevance":"high","symbol":"UTHR","type":"security"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; no prior filing state/diff is included beyond the single Form 4 text.","The excerpt shows multiple Common Stock line items with quantities and weighted average prices, but it is not fully clear from the cleaned text which specific quantity corresponds to each stated trade price range.","No total number of shares sold across all line items is explicitly summed in the provided text."],"key_facts":["SEC filing is Form 4 (SEC Act: 1934 Act) filed as of 2026-04-16; conforming period of report is 2026-04-16.","Reporting person: Paul Mahon, EVP & General Counsel, for United Therapeutics Corp.","The filing states the transaction is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into on August 11, 2025.","The transaction was executed in multiple trades; prices ranged from $573.865 to $574.83 (weighted average price reported as $574.03 for one line item).","Additional trade price ranges are stated in the text: $574.95 to $575.85; $575.97 to $576.92; $577.00 to $577.95; $578.00 to $578.53 (each with weighted average price language in the provided text).","The filing includes multiple line items for Common Stock with quantities and weighted average prices shown in the cleaned text (exact mapping of each quantity to each price range is not fully explicit in the provided excerpt)."],"numeric_claims":[{"label":"Form 4 filing date (as of)","value":"2026-04-16"},{"label":"Conformed period of report","value":"2026-04-16"},{"label":"10b5-1 plan entry date","value":"2025-08-11"},{"label":"Trade price range (one stated range)","value":"$573.865 to $574.83"},{"label":"Weighted average price shown (one line item)","value":"$574.03"},{"label":"Trade price range (additional stated range)","value":"$574.95 to $575.85"},{"label":"Trade price range (additional stated range)","value":"$575.97 to $576.92"},{"label":"Trade price range (additional stated range)","value":"$577.00 to $577.95"},{"label":"Trade price range (additional stated range)","value":"$578.00 to $578.53"}],"primary_claim":"Form 4 filed 2026-04-16 reports Paul Mahon\u2019s stock option exercise and sale of resulting United Therapeutics common shares pursuant to a 10b5-1 plan dated August 11, 2025.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) disclosed in an SEC Form 4 that Paul Mahon (EVP & General Counsel) exercised stock options and sold shares on 2026-04-16 under a pre-arranged 10b5-1 plan.","topics":["SEC Form 4","insider trading","stock option exercise","10b5-1 plan","common stock sales"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260416","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001231589-26-000010.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel